drugset / Trial / NCT00999518
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
RandomizedParallel-groupDouble-blindTreatment
Summary
In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary urgency. Only one dose was studied, and tanezumab was well tolerated. In this study, the hypothesis being tested is that tanezumab will show efficacy at several doses on reducing pain with sufficient tolerability. Tanezumab's safety will also be assessed at different dose levels
Timeline
- Start
- 2010-01-22
- Primary completion
- 2010-11-17
- Completion
- 2011-01-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tanezumab | Monoclonal antibody | 1 mg | Subcutaneous |
| Subject | Tanezumab | Monoclonal antibody | 2.5 mg | Subcutaneous |
| Subject | Tanezumab | Monoclonal antibody | 10 mg | Subcutaneous |
| Subject | Tanezumab | Monoclonal antibody | 20 mg | Subcutaneous |